Premium
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment
Author(s) -
Yip L.,
Deng J.F.
Publication year - 2017
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.13854
Subject(s) - idarucizumab , dabigatran , medicine , pharmacology , warfarin , atrial fibrillation